Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of BRAINSTORM CELL THERAPEUTICS INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001137883.
Disclosed value leader
Sankesh Abbhi
Comparable rows
2/18
Latest evidence
24 Jul 2026
- Public ticker
- BCLI on OTC
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 18
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
24 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001137883
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BRAINSTORM CELL THERAPEUTICS INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Sankesh Abbhi
Comparable rows
2/18
Latest evidence
24 Jul 2026
13D/G
3/4/5
Lead comparable stake: 10%
16 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 18 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
2 of 18 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 2
ARMISTICE CAPITAL, LLC
10%
Jacob A. Frenkel
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 18 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
10%
|
$789,250
717,500 shares
|
+$459,747 | 31 Mar 2025 |
| Jacob A. Frenkel |
3/4/5
Director
|
5.7%
|
$9,981
343,777 shares
|
— | 24 Jul 2026 |
| Sankesh Abbhi |
3/4/5
Director
|
—
class O/S missing
|
$3,860,181
2,175,853 shares
|
— | 10 Dec 2021 |
| Ralph Dr. Kern |
3/4/5
COO and Chief Medical Officer
|
—
class O/S missing
|
$396,174
223,310 shares
|
— | 06 Mar 2022 |
| Malcolm S. Taub |
3/4/5
Director
|
—
class O/S missing
|
$137,195
77,332 shares
|
— | 15 Dec 2021 |
| Chaim Lebovits |
3/4/5
President & CEO
|
—
mixed-class rows
|
$76,232
2,134,349 shares
mixed-class rows
|
— | 26 Feb 2026 |
| Kirk Taylor |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$62,094
115,000 shares
mixed-class rows
|
— | 01 May 2023 |
| June Sherie Almenoff |
3/4/5
Director
|
—
class O/S missing
|
$23,374
13,175 shares
|
— | 15 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to BRAINSTORM CELL THERAPEUTICS INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Sankesh Abbhi
Net 12M change
$0
Latest report
24 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sankesh Abbhi | Director | $3,860,181 | Mixed | 10 Dec 2021 | ||
| Ralph Dr. Kern | COO and Chief Medical Officer | $396,174 | Mixed | 06 Mar 2022 | ||
| Malcolm S. Taub | Director | $137,195 | Mixed | 15 Dec 2021 | ||
| Chaim Lebovits | President & CEO | $76,232 | Mixed | 26 Feb 2026 | ||
| Kirk Taylor | Chief Medical Officer | $62,094 | Mixed | 01 May 2023 | ||
| June Sherie Almenoff | Director | $23,374 | Mixed | 15 Dec 2021 | ||
| Ibrahim B. Dagher | Director | $18,130 | Mixed | 26 Feb 2026 | ||
| Uri Yablonka | EVP & Chief Business Officer, Director | $15,610 | Mixed | 26 Feb 2026 | ||
| Hartoun Hartounian | Director | $11,856 | Mixed | 26 Feb 2026 | ||
| Stacy Lindborg | Director | $10,996 | Mixed | 26 Feb 2026 | ||
| Alla Patlis | Interim Chief Financial Officer & Controller | $10,112 | Mixed | 26 Feb 2026 | ||
| Jacob A. Frenkel | Director | $9,981 | Mixed | 24 Jul 2026 | ||
| Irit Arbel | Director | $9,360 | Mixed | 26 Feb 2026 | ||
| Nir Naor | Director | $7,174 | Mixed | 26 Feb 2026 | ||
| Anthony J. Polverino | Director | $5,866 | Mixed | 26 Feb 2026 | ||
| Menghisteab Bairu | Director | $5,472 | Mixed | 26 Feb 2026 | ||
| Peter J. Pitts | Executive Chairman, Director | Mixed | 24 Jul 2026 |
Recent insider transactions for BRAINSTORM CELL THERAPEUTICS INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jacob A. Frenkel | BCLI | Common Stock | Award | 41% | 100,000 | 343,777 | 24 Jul 2026 | Direct | ||
| Peter J. Pitts | BCLI | Stock Option (Right to Buy) | Award | 900,000 | 900,000 | 24 Jul 2026 | Direct | |||
| Chaim Lebovits | BCLI | Common Stock | Award | 895.7% | 1,800,000 | 2,000,960 | 26 Feb 2026 | Direct | ||
| Uri Yablonka | BCLI | Common Stock | Award | 219.1% | 150,000 | 218,464 | 26 Feb 2026 | Direct | ||
| Alla Patlis | BCLI | Common Stock | Award | 225.5% | 100,000 | 144,349 | 26 Feb 2026 | Direct | ||
| Jacob A. Frenkel | BCLI | Common Stock | Award | 456.9% | 200,000 | 243,777 | 26 Feb 2026 | Direct | ||
| Irit Arbel | BCLI | Common Stock | Award | 292.3% | 120,000 | 161,054 | 26 Feb 2026 | Direct | ||
| Menghisteab Bairu | BCLI | Stock Option (Right to Buy) | Award | 150,000 | 150,000 | 26 Feb 2026 | Direct | |||
| Anthony J. Polverino | BCLI | Stock Option (Right to Buy) | Award | 150,000 | 150,000 | 26 Feb 2026 | Direct | |||
| Hartoun Hartounian | BCLI | Stock Option (Right to Buy) | Award | 225,000 | 225,000 | 26 Feb 2026 | Direct | |||
| Stacy Lindborg | BCLI | Stock Option (Right to Buy) | Award | 150,000 | 150,000 | 26 Feb 2026 | Direct | |||
| Nir Naor | BCLI | Stock Option (Right to Buy) | Award | 180,000 | 180,000 | 26 Feb 2026 | Direct | |||
| Ibrahim B. Dagher | BCLI | Stock Option (Right to Buy) | Award | 225,000 | 225,000 | 26 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.